Publications by authors named "M M Lievens"
Background: The recently approved AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine for older adults (RSVPreF3 OA) demonstrated high efficacy against RSV-related disease in ≥60-year-olds.
Methods: This ongoing phase 3 study in ≥60-year-olds evaluates immune persistence until 3 years after RSVPreF3 OA vaccination. Here, we describe interim results on humoral and cell-mediated immunogenicity, reactogenicity, and safety until 1 year post-dose 1.
Characterizing the Exponential Profile of W' Recovery Following Partial Depletion.
Med Sci Sports Exerc
September 2024
Purpose: The aim of this study was to characterize W' recovery kinetics in response to a partial W' depletion. We hypothesized that W' recovery following a partial depletion would be better described by a biexponential than by a monoexponential model.
Methods: Nine healthy men performed a ramp incremental exercise test, three to five constant load trials to determine critical power and W', and 10 experimental trials to quantify W' depletion.
Article Synopsis
- The RTS,S/AS01 malaria vaccine was tested for its effectiveness in a study involving 1,500 children aged 5-17 months in Ghana and Kenya, focusing on different dosing regimens.
- Four different groups received the vaccine in varying full and fractional doses, while a control group got a rabies vaccine.
- Results showed all RTS,S/AS01 regimens provided similar vaccine efficacy (25-43%) against new malaria infections, significantly reducing the number of infections over a 20-month follow-up period.
Background: The RTS,S/AS01E (RTS,S) malaria vaccine is recommended for children in malaria endemic areas. This phase 2b trial evaluates RTS,S fractional- and full-dose regimens in Ghana and Kenya.
Methods: In total, 1500 children aged 5-17 months were randomized (1:1:1:1:1) to receive RTS,S or rabies control vaccine.
Background: The only licensed malaria vaccine, RTS,S/AS01 , confers moderate protection against symptomatic disease. Because many malaria infections are asymptomatic, we conducted a large-scale longitudinal parasite genotyping study of samples from a clinical trial exploring how vaccine dosing regimen affects vaccine efficacy (VE).
Methods: 1,500 children aged 5-17 months were randomized to receive four different RTS,S/AS01 regimens or a rabies control vaccine in a phase 2b clinical trial in Ghana and Kenya.